Telenav, Inc. (TNAV) Forms $5.65 Double Bottom; Supernus Pharmaceuticals, Inc. (SUPN) Had 7 Bullish Analysts

Among 10 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Supernus Pharmaceuticals had 35 analyst reports since August 26, 2015 according to SRatingsIntel. The company was upgraded on Monday, December 4 by Janney Capital. PiperJaffray downgraded the shares of SUPN in report on Monday, July 17 to “Neutral” rating. B. Riley & Co maintained the stock with “Buy” rating in Wednesday, November 8 report. The company was maintained on Tuesday, January 2 by Stifel Nicolaus. Jefferies maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Tuesday, September 5. Jefferies has “Buy” rating and $51.0 target. FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, November 20 with “Buy” rating. On Wednesday, July 5 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Stifel Nicolaus maintained it with “Buy” rating and $47.0 target in Friday, September 1 report. The firm has “Hold” rating given on Thursday, August 3 by Piper Jaffray. The firm earned “Neutral” rating on Monday, July 18 by Piper Jaffray. See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) latest ratings:

02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $48.0 Maintain
04/12/2017 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $47 Upgrade
20/11/2017 Broker: FBR Capital Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: FBR Capital Rating: Buy New Target: $50.0
08/11/2017 Broker: B. Riley & Co Rating: Buy Old Target: $53 New Target: $50 Maintain
08/11/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
27/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $41.0 Maintain
23/10/2017 Broker: Cowen & Co Rating: Buy New Target: $50.0 Maintain
20/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $47.0 Maintain

Telenav, Inc. (TNAV) formed double bottom with $5.20 target or 8.00% below today’s $5.65 share price. Telenav, Inc. (TNAV) has $250.36 million valuation. The stock increased 0.89% or $0.05 during the last trading session, reaching $5.65. About 81,419 shares traded. Telenav, Inc. (NASDAQ:TNAV) has risen 88.62% since January 31, 2017 and is uptrending. It has outperformed by 71.92% the S&P500.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.34, from 1.32 in 2017Q2. It dived, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Sg Americas Secs Ltd Limited Liability Company stated it has 22,436 shares. Millennium Mngmt Ltd Co has 534,509 shares for 0.03% of their portfolio. Barclays Public Limited has 0% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). State Of Tennessee Treasury Department has 44,412 shares. Moreover, Mutual Of America Mgmt Ltd Liability Co has 0.26% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 402,565 shares. Ameritas Prtnrs owns 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 4,051 shares. Susquehanna Ltd Liability Partnership owns 100,937 shares. 2,710 were reported by Fortaleza Asset Mngmt Incorporated. Adams Diversified Equity Fund reported 18,400 shares. Ranger Limited Partnership invested 2.97% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Citadel Advisors Limited Liability reported 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Great West Life Assurance Company Can holds 68,659 shares or 0.01% of its portfolio. Morgan Stanley reported 218,346 shares. Parametric Associate Ltd Llc invested in 335,847 shares or 0.01% of the stock. 28,165 were reported by White Pine Cap Ltd Liability Company.

The stock decreased 1.95% or $0.8 during the last trading session, reaching $40.25. About 890,512 shares traded or 52.95% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since January 31, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.06 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 36.62 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Since August 16, 2017, it had 0 insider purchases, and 11 sales for $15.48 million activity. 50,000 shares valued at $2.38M were sold by PATRICK GREGORY S on Thursday, September 7. Vaughn Victor sold $2.21M worth of stock or 55,000 shares. $960,716 worth of stock was sold by Bhatt Padmanabh P. on Monday, January 22. Schwabe Stefan K.F. had sold 95,000 shares worth $4.43M on Thursday, September 7.

Investors sentiment decreased to 0.81 in 2017 Q3. Its down 0.16, from 0.97 in 2017Q2. It fall, as 12 investors sold Telenav, Inc. shares while 24 reduced holdings. 7 funds opened positions while 22 raised stakes. 17.38 million shares or 6.37% less from 18.57 million shares in 2017Q2 were reported. Dimensional Fund Advisors L P has 0% invested in Telenav, Inc. (NASDAQ:TNAV). Bankshares Of New York Mellon Corp has 125,391 shares for 0% of their portfolio. Alliancebernstein Lp reported 22,100 shares. Geode Ltd, Massachusetts-based fund reported 270,742 shares. Ameriprise Fincl invested 0% of its portfolio in Telenav, Inc. (NASDAQ:TNAV). 408,300 were reported by Renaissance Technologies Ltd Liability Corp. Moreover, Axa has 0.01% invested in Telenav, Inc. (NASDAQ:TNAV) for 219,080 shares. Equitec Proprietary Markets Limited reported 169,263 shares stake. State Common Retirement Fund owns 0% invested in Telenav, Inc. (NASDAQ:TNAV) for 347,305 shares. D E Shaw & Inc, New York-based fund reported 118,994 shares. California State Teachers Retirement Sys owns 48,004 shares. Goldman Sachs Gp Incorporated reported 10,425 shares. Northern Corp stated it has 338,385 shares. Essex Investment Co Ltd Liability reported 0.21% stake. 50,339 are owned by Morgan Stanley.

Among 5 analysts covering Telenav (NASDAQ:TNAV), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Telenav has $15 highest and $9.0 lowest target. $11.13’s average target is 96.99% above currents $5.65 stock price. Telenav had 7 analyst reports since August 24, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, October 17 by FBR Capital. The firm has “Buy” rating given on Monday, July 10 by Northland Capital. The firm has “Buy” rating given on Thursday, December 21 by Craig Hallum. B. Riley & Co initiated Telenav, Inc. (NASDAQ:TNAV) on Monday, August 24 with “Buy” rating. The rating was downgraded by Sidoti on Friday, January 20 to “Neutral”.